Efficacy of Combination Therapy with Pregabalin in Neuropathic Pain: A Preclinical Study in the Rat L5 Spinal Nerve Ligation Model
Kazutaka Nozawa,Yusuke Karasawa,Yuka Shidahara,Takahiro Ushida
DOI: https://doi.org/10.2147/JPR.S383981
IF: 2.8319
2022-10-31
Journal of Pain Research
Abstract:Kazutaka Nozawa, 1 Yusuke Karasawa, 1 Yuka Shidahara, 2 Takahiro Ushida 3 1 Medical Affairs, Viatris Pharmaceuticals Japan Inc., Minato-ku, Tokyo, Japan; 2 Bioscience Business Division, KAC Co., Ltd, Ritto, Shiga, Japan; 3 Multidisciplinary Pain Center, Aichi Medical University, Nagakute, Aichi, Japan Correspondence: Kazutaka Nozawa, Medical Affairs, Viatris Pharmaceuticals Japan Inc, Minato-ku, Tokyo, Japan, Tel +81 80-5001-3029, Email Purpose: Neuropathic pain is sometimes difficult to manage because of limited efficacy of analgesic monotherapy even at high doses. Combination therapy may help address this issue, but there is little evidence for its effectiveness. Therefore, we evaluated the efficacy of combination therapy with pregabalin, an anchor drug for treating neuropathic pain, using the rat L5 spinal nerve ligation model. Methods: Experiments were performed on four-week-old L5 spinal nerve ligated male Sprague-Dawley rats. Mechanical allodynia was assessed using the von Frey test, where the 50% withdrawal threshold was evaluated for five drugs: pregabalin, duloxetine, venlafaxine, tramadol, and celecoxib. The single-drug experiment included 112 rats, where each drug was tested independently. Median effective doses (ED 50 s) were determined. Combinations of pregabalin with each of the other four drugs were tested (n=84). The 50% withdrawal threshold in the von Frey test was evaluated. The ED 50 of each combination was determined experimentally. Isobolographic analyses were conducted to assess the synergistic potential of the drug combinations, excluding pregabalin-celecoxib, since the ED 50 of celecoxib could not be determined. Results: In the single-drug experiment, all drugs except celecoxib resulted in a dose-dependent increase in the 50% withdrawal threshold 2 h after administration, with a maximum possible effect ranging from 4.4% to 79.6%. Similarly, all pregabalin combinations demonstrated a dose-dependent increase in the 50% withdrawal threshold, with pregabalin-tramadol showing the greatest increment. Isobolographic analysis of this combination revealed synergistic effects. Specifically, the combination index was γ=0.4 (< 1). Combinations of pregabalin with duloxetine and venlafaxine demonstrated additive (γ=0.9) and antagonistic effects (γ=2.0), respectively. Conclusion: This study demonstrated that combination of pregabalin with tramadol has synergistic antiallodynic effects, while that with duloxetine has additive effects. Moreover, pregabalin combined with venlafaxine was potentially antagonistic. Pregabalin combined with tramadol may serve as a promising drug combination for the effective management of neuropathic pain. Keywords: analgesic, animal model, isobologram, synergistic effects Neuropathic pain is defined as pain caused by a lesion or a disease of the somatosensory nervous system, 1 which alters sensory signals transmitted to the brain and spinal cord. 2 Common characteristics of neuropathic pain include persistent burning and painful sensations, numbness, and increased sensitivity to touch. 2 The global prevalence of this condition is estimated to be 7%–10%. 2,3 Neuropathic pain is frequently associated with sleep disruption and anxiety, negatively affecting patients' overall mental well-being and reducing their quality of life. 4 Pharmacotherapy is currently the most commonly used treatment to manage neuropathic pain. First-line treatments including gabapentinoids such as gabapentin and pregabalin and serotonin-norepinephrine reuptake inhibitors (SNRIs) such as duloxetine and venlafaxine and second-line treatment including the weak opioid tramadol are recommended by the International Association for the Study of Pain. 5 In the clinical setting, nonsteroidal anti-inflammatory drugs (NSAIDs) such as celecoxib are prescribed for mixed pain consisting of nociceptive and neuropathic components. However, their efficacy in treating neuropathic pain is limited. 6 Neuropathic pain is associated with the upregulation of voltage-gated calcium channels (VGCCs), specifically the α 2 -δ-1 subunit, in the dorsal horn and dorsal root ganglion of the spinal cord, 7,8 causing increased neural excitation and consequently, neuropathy. 8,9 Pregabalin, an anticonvulsant drug, binds to the α 2 -δ auxiliary subunits to reduce calcium influx, lowering neurotransmitter release and, consequently, overall neuronal excitability. 8 Its neuropathic pain–relieving properties have been demonstrated in several preclinical and clinical studies. 8 SNRIs are thought to relieve neuropathic pain by im -Abstract Truncated-
clinical neurology